Categories
World News

Antitrust regulator orders Tencent Music to surrender music label rights

Photo illustration of the logo of Tencent Music Entertainment (TME), a Chinese company that develops music streaming services.

Pavlo Gonchar | SOPA pictures | LightRocket via Getty Images

The Chinese antitrust authorities have ordered Tencent to give up its exclusive music licensing rights with international record labels and fined the company as Beijing continues to crack down on its internet giants at home.

The State Administration for Market Regulation (SAMR) on Saturday fined the company 500,000 yuan ($ 77,141) for violating the regulations when it acquired China Music in 2016.

In response, Tencent said it would abide by the regulator’s decision and “meet all regulatory requirements, meet our social responsibilities and contribute to healthy competition in the market.”

It comes as Beijing continues to crack down on its domestic tech companies that have grown into some of the most valuable companies in the world. The crackdown in recent months has ranged from the Ant Group’s $ 34.5 billion initial public offering suspension last year to Alibaba’s $ 2.8 billion antitrust fine.

In April, the SAMR called 34 companies, including Tencent and ByteDance, and ordered them to conduct self-inspections to comply with antimonopoly rules.

This is the latest news. Please check again for updates.

Categories
Politics

Bitcoin ETF ought to have been accredited some time in the past, SEC regulator Peirce says

Hester Peirce, Commissioner for the U.S. Securities and Exchange Commission (SEC), Center, listens during a House Financial Services Committee hearing in Washington, DC, the United States, on Tuesday, September 24, 2019.

Andrew Harrer | Bloomberg | Getty Images

Hester Peirce is at a loss.

For years, the Securities and Exchange Commission, of which Peirce is a member, has rejected requests from national stock exchanges and financial companies to list securities that track the performance of the popular digital currency Bitcoin.

Back in the day – let’s say 10 years ago – concerns about possible market manipulation and liquidity might have made sense, but things have changed.

“This is probably the biggest and most frequently asked question I get: When will the SEC approve a Bitcoin publicly traded product?” Commissioner Peirce said in an interview with CNBC on Thursday.

“I thought if we had applied our standards as we applied them to other products, we would have already approved one or more of them,” she said. “With every day that goes by, the rationale we have used in the past for not being approved seems to be weakening.”

The SEC applies a “unique, elevated standard” to filings related to digital assets, it wrote in 2020. And it has argued that the agency is asking exchanges and potential ETF sponsors for assurances beyond what they do for traditional, stock-based demands products.

“People with a regulatory mindset say, ‘Oh wait, the market for Bitcoin looks a little different from the markets we’re used to,'” said Peirce on Thursday.

Now, she added, the Bitcoin market looks more like an established market with more institutional and established retail investors involved.

“So I think the markets have matured quite a bit,” said Peirce.

Renewed demands for a SEC-approved Bitcoin ETF come just weeks after the regulator announced its ruling on approving an application by VanEck to list shares of its Bitcoin Trust on the Chicago Board of Exchange’s BTZ Exchange move.

Regulators said in a letter dated June 16 that they would take additional time to seek comments from the public. In particular, the SEC asks investors and scientists for their opinion on whether Bitcoin ETFs could be susceptible to manipulation or whether Bitcoin itself is sufficiently distributed and therefore resistant to similar underhand manipulation.

But Peirce, a Republican named one of the SEC’s five commissioners by former President Donald Trump, has long denounced what she sees as double standards for Bitcoin products in her own agency.

Perhaps her sharpest objection came in a dissent in 2018, when she argued that the SEC should have approved an application by the Chicago Board of Exchange’s Bats BTZ Exchange to list and trade shares in the Winklevoss Bitcoin Trust.

“By excluding the approval of cryptocurrency-based ETPs for the foreseeable future, the Commission is operating a performance regulation,” she wrote at the time. “Bitcoin is a new phenomenon and its long-term viability is uncertain. It can be successful, it can fail. However, the commission is not well positioned to assess the likelihood of either outcome for Bitcoin or other assets. “

Three years later, VanEck’s current filing – much like pending Bitcoin ETF filings from Fidelity, Cathie Wood’s Ark Invest, and a few others – is viewed by the industry as an SEC litmus test now led by a cryptocurrency expert, Chairman Gary Gensler becomes.

Former chairman of the Commodity Futures Trading Commission, Gary Gensler, testifies at a US Senate Banking Committee hearing on systemic risk and market oversight on Capitol Hill in Washington on May 22, 2012.

Jonathan Ernst | Reuters

His appointment as head of the SEC by President Joe Biden, and his subsequent Senate confirmation, met with optimism from many in the crypto community as he is seen as a skilled hand in creating novel financial rules.

Gensler, who taught crypto courses at the Massachusetts Institute of Technology, is perhaps best known for his influential tenure as chairman of the Commodity Futures Trading Commission in the Obama administration. There Gensler helped develop and introduce a new supervisory system for the swap market, which was largely unregulated before the financial crisis.

Even if the Democrat Gensler does not necessarily agree with the Trump-appointed Peirce on all issues, they can join a more proactive SEC on Bitcoin regulation.

Rejecting Bitcoin ETF applications not only carries the risk of double standards, it can also provide few, more dangerous alternatives to thousands of investors.

“The Complications of Not Approval [an application] get stronger because people are looking for other ways to do the same things that they would do with an exchange traded product, “she said.” They are looking for other types of products that are not that easy to get in and out of maybe look at companies that are somehow related to bitcoin or crypto in a broader sense. “

Bitcoin itself has taken a violent start to summer and has fainted its price by more than 40% in the past three months. Although it remains one of the most actively traded digital assets, some market watchers say Bitcoin is at a critical juncture.

“It looks like it might be preparing for a $ 30,000 retest, and that could be critical,” Art Cashin, director of NYSE floor operations at UBS, said Thursday. “If you crack $ 30,000, traders will see if there is a trapdoor, a cascade sell-off, to follow.”

Zoom In Icon Arrows pointing outwards

Its dizzying ups and downs even come as a growing number of companies and banks, including payment companies Square and PayPal, began to facilitate Bitcoin transactions.

Meanwhile, the Bank of New York Mellon announced in February that it would start funding Bitcoin, a major development given that it is both the oldest bank in the country and a leader in custody banking.

Late on Friday morning, Bitcoin rose 1.6% to $ 33,550.

Despite the volatile fluctuations in the price of the currency, Peirce remains convinced that a Bitcoin ETF is overdue.

It is not the SEC’s job to approve or deny requests based on the merits of the investment itself, she said Thursday, especially if the exchanges meet legal requirements to protect investors from fraud.

“Bitcoin is so decentralized now. The number of nodes involved in Bitcoin is large and the number of people who have an interest in keeping this work decentralized is very large, ”she said. “People should make their own decisions: if people don’t want to buy bitcoin because they think it’s tampered with, they shouldn’t buy bitcoin.”

Categories
Business

EU medicines regulator finds doable hyperlink between AstraZeneca Covid vaccine and blood clots

Syringes are filled with Astrazeneca’s vaccine in the pharmacy.

Christopher Neundorf | Image Alliance | Getty Images

LONDON – Europe’s Medicines Agency announced on Wednesday a possible link between the coronavirus vaccine developed by AstraZeneca and Oxford University and rare blood clotting problems in adults who received the shot.

It comes after a review of all currently available evidence in extremely rare cases of unusual blood clots in some vaccinated individuals.

Emer Cooke, executive director of the European Medicines Agency, said in a televised press conference that the regulator’s safety committee “has confirmed that the overall benefits of the AstraZeneca vaccine in preventing Covid-19 outweigh the risks of side effects.”

“A plausible explanation for these rare side events is an immune response to the vaccine that is similar to that seen in heparin-treated patients,” said Cooke, noting that it was heparin-induced thrombocytopenia.

The EMA has commissioned further research to investigate the link between the vaccine and blood clots, and said its safety committee had concluded that unusual blood clots with low platelets should be listed as “very rare” side effects of the shot. It also drew the public’s attention to other possible side effects that are flagged as adverse drug reactions on the product information of the vaccine.

The European Medicines Agency said it was “of great importance” that health professionals and those receiving the Oxford-AstraZeneca vaccine are aware of these risks and look out for possible symptoms, typically in the first two weeks after vaccination occur.

“These include, for example, shortness of breath, chest pain, swelling in the leg, persistent abdominal pain, neurological symptoms such as severe or persistent headaches or blurred vision and skin bruises beyond the injection site,” said Dr. Sabine Straus, chair of EMA’s security committee, said at the same press conference.

AstraZeneca’s shares fell nearly 1% during afternoon trading in London.

The Oxford-AstraZeneca shot has been followed by safety concerns in recent weeks, and several European countries temporarily stopped using the vaccine last month.

The EMA said on March 31 that it had found the shot to be safe and effective, but added that it could not rule out the possibility of a causal link between the vaccine and coagulation events, so the investigation will continue.

The World Health Organization, the UK Medicines Agency and the International Society on Thrombosis and Hemostasis have all stated that the benefits of administering the Oxford-AstraZeneca shot far outweigh the risks.

AstraZeneca previously said that its studies didn’t find a higher risk of blood clots as a result of its vaccine.

Most countries have since resumed the use of the shot, but many have suspended vaccinations for certain age groups.

A senior European Medicines Agency official said Tuesday that there was a clear “link” between the Oxford-AstraZeneca vaccine and very rare blood clots in the brain, although the direct cause was not yet known.

In an interview with the Italian newspaper Il Messaggero published on Tuesday, Marco Cavaleri, chairman of the EMA’s vaccine evaluation team, said: “In my opinion, we can now say that there is a link to the vaccine, but we are still me don’t know what is causing this reaction. “

The EMA then denied in a statement to Agence France-Presse that it had made a connection between the Oxford-AstraZeneca shot and rare blood clots.

UK vaccine study in children paused

The drug and health products regulator, which approved the Oxford-AstraZeneca vaccine for use in the UK, examined the data after a handful of reports – in both the UK and continental Europe – of serious but rare blood clots, some of which were fatal .

A UK study of the Oxford AstraZeneca vaccine in children has already been paused while the drug agency investigated a possible link between the shot and the bleeding disorders, particularly cases of blood clots in veins in the brain known as cerebral venous sinus thrombosis (CVST) as well Thrombocytopenia (low levels of platelets in the blood that help blood to clot).

The UK government noted that as of March 24th inclusive, there were 22 reports of CVST and 8 reports of other low platelet thrombosis events totaling 18.1 million doses of the AstraZeneca vaccine (one shot with two doses). given up to this date.

People are waiting in a vaccination center in Cologne on April 5, 2021.

Marius Becker | Image Alliance | Getty Images

“We need to know more about those affected and understand exactly how the diseases came about while many other questions remain open,” said Adam Finn, professor of pediatrics at Bristol University, UK, ahead of the announcement on Wednesday.

“There are some things that are very clear, however. The first is that these cases are indeed very rare. The second is that the vaccines available and used in the UK are very effective in preventing COVID,” said Finn.

“In short, if you are currently offered a dose of Oxford AstraZeneca vaccine, your chances of staying alive and staying healthy will go up if you take the vaccine and go down if you don’t.”

– CNBC’s Holly Ellyatt contributed to this report.

Categories
Health

European nations resume utilizing AstraZeneca Covid vaccine after regulator OK

A dose of the Oxford / AstraZeneca coronavirus vaccine is being made by a member of the Hampshire Fire and Rescue Service of the Basingstoke Fire Station, which has been set up as a vaccination center and where crews are still answering 999 calls on February 4, 2021 in Basingstoke, England.

WPA pool | Getty Images

LONDON – The European Medicines Agency has decided that the AstraZeneca coronavirus vaccine is safe and effective, despite some concerns about possible side effects.

Thursday’s announcement comes after more than a dozen EU countries stopped using the AstraZeneca shot developed with Oxford University after around 30 cases of blood clots. Some other countries have stopped using individual batches of the vaccine.

France, Germany, Italy, the Netherlands, Portugal, Spain and several other European nations are now planning to resume the use of the shot after the regulatory authority’s OK.

The EMA said Thursday that the vaccine’s benefits outweighed the risks. No batch or quality problems with the vaccine were found, although an association with the blood clot incidents could not be definitively ruled out.

“This is a safe and effective vaccine,” said Emer Cooke, EMA Executive Director, at a news conference Thursday.

“The benefits of protecting people from Covid-19, with the associated risks of death and hospitalization, outweigh the potential risks. The committee also concluded that the vaccine was not associated with an increase in the overall risk of thromboembolic events or blood clots. … We still cannot rule out a definitive link between these cases and the vaccine. “

The regulator said it will continue to investigate possible links between rare blood clots and the vaccine. It will also update its guidelines for the vaccine to clarify the potential risks.

Suspensions

The suspensions were not uniform across the 27 member states of the European Union and a number of nations continued to use the AstraZeneca shot in their vaccination campaigns.

Austria became the first country to stop using a certain batch of AstraZeneca shots last week after a 49-year-old woman who received the vaccine died.

Reports of blood clots elsewhere followed, albeit in a very small number of people, causing other leaders to suspend use and await a reassessment by the region’s health authority.

The EMA said in its review that the vaccine may be associated with very rare cases of thrombocytopenia-related blood clots, which are low platelet levels, including rare cases of blood clots in the vessels that drain blood from the brain known as CVST.

“These are rare cases – around 20 million people in the UK and EEA (European Economic Area) had received the vaccine by March 16, and the EMA had only looked at 7 cases of multiple blood clots and 18 cases of CVST. One cause A link to the vaccine has not been established but it is possible and deserves further analysis, “added the EMA in a statement.

AstraZeneca’s vaccine is widely used in the UK but has not yet been approved by the US authorities.

The benefits outweigh the risks.

The World Health Organization said Wednesday that “vaccination against Covid-19 will not reduce disease or death for other reasons. Thromboembolic events are known to be common.”

In addition, WHO said the response from some EU countries had shown that “the surveillance system is working and that there are effective controls in place”. Nonetheless, the institution reiterated its belief that “the benefits of the AstraZeneca vaccine outweigh the risks and recommends that vaccinations be continued”.

The UK Medicines Agency also said Thursday that people should continue to receive the AstraZeneca shot.

Some health professionals have raised major concerns about discontinuing use of this vaccine. Earlier this week, Cooke, of the EMA, said the institution was concerned the suspensions could affect people’s confidence in vaccines.

Recent concerns about the side effects stem from the uncertainty of some EU countries about an alleged lack of data on the effectiveness of the AstraZeneca vaccine in the elderly. However, these countries later decided to use the shot for vaccination.

Situation in Europe “worsening”

The distribution of vaccines is vital in Europe from both a health and an economic perspective.

The President of the European Commission, Ursula von der Leyen, said on Wednesday: “The epidemiological situation is deteriorating.”

“We are seeing a third wave forming in Member States and we know we need to speed up vaccination rates,” she added.

The EU aims to vaccinate 70% of its adult population by the end of summer.

The data presented on Wednesday suggests that the bloc is on track to achieve this goal, provided that drug companies honor their supply contracts over the next three months and member states use them successfully.

– CNBC’s Sara Salinas contributed to this report.

Categories
Business

Biden’s Picks for Monetary Regulator Jobs Emphasize Transparency and Equity

President Biden’s decision to head two key regulatory agencies – the Securities and Exchange Commission and the Consumer Financial Protection Bureau – highlighted two goals Tuesday: transparency and control of powerful interests. He stressed that those who break the law must be held accountable for their actions.

In a full hearing before the Senate Banking Committee, SEC candidate Gary Gensler and consumer bureau candidate Rohit Chopra gave details of their positions on issues such as climate change, stock market volatility, student loans and cryptocurrencies.

Faced with questions from Republicans who suspected Mr Biden might use regulatory agencies to advance liberal policies, the two candidates insisted they would not extend the powers entrusted to the agencies – but were sure how to exercise it would.

For example, Mr Gensler defended the need for companies to disclose climate risks and diversity efforts, saying these issues are a top priority for many investors. “I think diversity in board and leadership roles is beneficial to decision-making, and that is something I am committed to with the SEC,” said Gensler.

Republicans asked whether it was appropriate for the SEC to impose such standards on companies, but Mr. Gensler repeatedly stressed that he was talking about transparency for investors and not instructing companies to take certain actions.

Mr. Gensler said corporate disclosure rules boil down to “materiality” and what a “reasonable investor” wants to know. He said the standard was largely developed by the courts but has changed over time.

“It’s the investor community that can decide,” Gensler said, not companies. And with “tens of trillions of assets invested,” he said, they are looking for information on climate risks.

The hearing was milder than expected, especially for Mr Chopra, who ran an agency that is often demonized by Republicans. Mr. Chopra is a close ally of Senator Elizabeth Warren, the Massachusetts Democrat who inspired the creation of the Consumer Bureau, and is expected to aggressively use the agency’s wide-ranging powers to set and enforce rules, including by serving businesses Forcing consumers to pay refunds they have done wrong.

Senator Patrick J. Toomey of Pennsylvania, the senior Republican, echoed his party’s criticism of the consumer bureau in his opening speech, calling it “arguably the most inexplicable agency in federal government history” and one that has persecuted an “activist”. Anti-business agenda. “

But this criticism was at times undercut by members of his own party. Throughout the hearing, Republicans have called for tighter surveillance on companies that harm consumers, especially those targeting members of the military and the elderly, on several occasions. Senator John Kennedy, Republican of Louisiana, suggested that Congress tighten the rules on credit bureaus, forcing them to be more responsive to consumer complaints about inaccurate information in credit reports.

Senators from both parties questioned Mr. Gensler about the GameStop trading frenzy in January, specifically how brokers like Robinhood, the online trading platform at the center of the rally, are making money.

Mr. Gensler assured several senators that, under his leadership, the SEC would investigate the aftermath of the sudden rise and fall in the video game company’s stock and sales of customer deals – called the payment for the flow of orders – that fund popular trading platforms that don’t charge commissions. Mr Gensler said the practice needs to be reviewed to see if it is harming retail investors.

Mr. Chopra, currently commissioner for the Federal Trade Commission, also discussed popular tech companies and criticized the FTC for what he believed to be lax enforcement efforts. The commission’s deal with Facebook on how to deal with people’s private information in 2019, which included a $ 5 billion fine, did not resolve the company’s core problems, he said.

Silicon Valley’s powerhouses will be in the crosshairs of the consumer bureau, he said, saying it is critical for the agency to “look closely” and “look at the implications for our privacy” at big tech companies entering the financial services market and privacy to evaluate our personal information. “

Student loan oversight is another priority for Mr Chopra, who previously served as the first student loan ombudsman at the Consumer Bureau. Some of the problems plaguing the mortgage industry prior to the housing crash – including rampant maintenance failures that hurt borrowers seeking relief to which they were legally entitled – had crept into the student loan market, he said.

Mr Chopra said he will work with the education department and attorneys general to ensure student loan service providers and other industry players are complying with the law. “It’s very, very important that we get it right,” he said.

He also said the office must closely monitor the property market as eviction moratoriums and other emergency chemical relief efforts end. The consumer bureau warned this week that 11 million families – nearly 10 percent of US households – are in arrears with their payments and face eviction or foreclosure.

“We need to be prepared for potentially looming problems when it comes to forbearance that could lead to foreclosures,” said Chopra.

The sharpest moment of the hearing came when Mr Toomey pressed Mr Chopra on his previous criticism of lawmakers who had supported changes to curb consumer bureau independence. In a 2016 lecture, Mr. Chopra accused these lawmakers of “having shillings for predatory lenders,” a statement that Mr. Toomey asked Mr. Chopra to withdraw.

“I regret saying that,” replied Mr Chopra.

Mr. Gensler, who headed the Commodity Futures Trading Commission during the Obama administration and worked for the Senate Banking Committee decades ago, encountered fewer problems. Republicans shared some of his concerns about fair treatment of retail investors and noted his expertise in digital currencies, a subject Mr. Gensler taught at MIT

Mr. Gensler assured Senator Mike Rounds, Republican of South Dakota that he shared the Senator’s desire to support experiments in digital currency.

“These innovations were a catalyst for change,” said Gensler. “Bitcoin and other cryptocurrencies have brought new considerations to payments and financial inclusion, but they have also raised new investor protection issues that we have yet to consider.”

And when Mr. Kennedy asked Mr. Gensler why more people on Wall Street didn’t go to jail after the financial crisis a decade ago, Mr. Gensler said he agreed with the Louisiana Republican concerns but noted that the agency he was During the year the crisis headed only civil and not criminal law enforcement agencies.

“Those are questions I share with you,” said Mr. Gensler.

Categories
Health

AstraZeneca-Oxford Covid vaccine authorised to be used by European regulator

Head nurse Sam Foster is holding a vial of Oxford University / AstraZeneca COVID-19 vaccine on January 4, 2021 at Churchill Hospital in Oxford, South West England.

Steve Parsons | AFP | Getty Images

LONDON – The coronavirus vaccine developed by AstraZeneca and Oxford University has been approved by the European Medicines Agency, the European Medicines Agency.

The EMA said on Friday that it had assessed the safety and effectiveness of the Covid vaccine and recommended that the European Commission, the EU’s executive branch, give formal conditional marketing authorization.

It also said the shot would likely work in the elderly after a German vaccine committee recommended Thursday not to give the vaccine to those over 65.

“With this third positive opinion, we have further expanded the arsenal of vaccines available to EU and EEA member states to fight the pandemic and protect their citizens,” said Emer Cooke, Executive Director of EMA, in a statement on Friday.

“As in previous cases, the CHMP has rigorously evaluated this vaccine and the scientific basis of our work underpins our firm commitment to protecting the health of EU citizens,” said Cooke, referring to the EMA’s Committee on Medicinal Products for Human Use.

The vaccine is already being used in the UK, having received approval in late December, and now, along with the Pfizer BioNTech shot, which has already been approved for use in the UK, makes up most of the EU shocks administered in the country.

Approval comes at a difficult time for the EU as the vaccination program is at best sluggish and very prone to supply shortages.

He has been dealt two blows in the past few weeks, one from Pfizer, who announced that it would temporarily cut production while improving production capacity at its Belgian facility. Then last Friday it was reported that AstraZeneca would deliver far fewer cans to the block than originally expected due to production problems at its plants in the Netherlands and Belgium this spring.

The delays have sparked a crisis in the EU which has announced it will curb exports of coronavirus vaccines from the bloc to give citizens priority. These controls are expected to last until March.

On Wednesday, the EU called on AstraZeneca to do whatever it takes to deliver its agreement to supply millions of coronavirus vaccines, suggesting that the company is diverting some supplies from its UK manufacturing facilities to the EU.

German doubt

On Thursday, doubts arose about the possible approval of AstraZeneca’s vaccine after the German vaccine committee recommended that the vaccine only be offered to people between the ages of 18 and 64.

This is due to the fact that there is insufficient data to assess the effectiveness in people over 65 years of age.

Older study participants were later admitted to phase 3 clinical trials with the AstraZeneca shot, which took place in the UK and Brazil and earlier in South Africa. As a result, there are fewer data on effectiveness in those over 65.

AstraZeneca said this data would be collected when its study results were published in the medical journal The Lancet in December: “As older age groups were recruited later than younger age groups, there was less time to collect cases and, consequently, efficacy data in these cohorts The number of cases is currently limited, but additional data will be available in future analyzes, “it said.

On Friday when the AstraZeneca approval was announced, the EMA announced that older participants (over 55 years of age) had not yet had enough results to establish a number for the vaccine’s effectiveness in this group. However, it states that “protection is expected because an immune response is observed in this age group and is based on experience with other vaccines”.

Categories
Business

UK regulator approves Moderna Covid vaccine

CSL staff will be working in the laboratory on November 08, 2020 in Melbourne, Australia, where they will begin manufacturing the AstraZeneca-Oxford University’s COVID-19 vaccine.

Darrian Traynor | Getty Images

The UK regulator has approved Moderna’s coronavirus vaccine for use in the country, the Ministry of Health said on Friday.

It is the third Covid shot approved for use in the UK following previous vaccine approvals from Pfizer and BioNTech, as well as Oxford and AstraZeneca universities.

In a press release, the department announced that the Moderna vaccine met the “stringent standards for safety, efficacy and quality” set by the drug and health product regulator.

It added that the UK had ordered an additional 10 million doses of the vaccine, bringing the total to 17 million. They are expected to be available from spring.

This is a developing story and will be updated shortly.

Categories
Business

Biden to choose North Carolina environmental regulator to run EPA

Michael Regan listens as North Carolina Governor Roy Cooper announces that Regan will lead the North Carolina Environmental Quality Department at Executive Manson in Raleigh, NC on January 3, 2017.

Chuck Liddy | AP

President-elect Joe Biden will select Michael Regan, secretary for the North Carolina Department of Environmental Quality, to head the Environmental Protection Agency, a person familiar with the matter told CNBC.

Regan, 44, was Biden’s front runner and, if confirmed, will be the first black to head the agency.

Regan previously worked at the EPA for the Clinton and George W. Bush administrations and was the national program manager responsible for developing programs to improve energy efficiency, air quality and reduce air pollution.

Regan later worked at the Environmental Defense Fund, where he made efforts to contain the effects of climate change and air pollution.

He will play a crucial role in supporting Biden’s aggressive plan to combat global warming and transform the US economy from fossil fuels to clean energy. Regan is also expected to be heavily involved in environmental racism.

“Regan has dedicated his career to environmental work, promoting clean energy, combating climate change and tackling coal ash pollution,” said Abigail Dillen, president of Earthjustice, an environmental law nonprofit. “As the EPA administrator, Regan will play a key role in solving the climate crisis and protecting the health of all communities.”

Biden also intends to appoint Rep. Deb Haaland, DN.M., as his Home Secretary. If this were confirmed, Haaland would be the first Native American to be appointed cabinet secretary. She would oversee the management and conservation of the land’s public land and natural resources, as well as the restoration of land that the Trump administration had opened up for drilling and other construction.

Read more from CNBC environment:
Joe Biden’s climate protection agenda faces an uncertain future in the Senate
Biden will rejoin the Paris Climate Agreement. Here’s what happens next

Biden has vowed to reintroduce the U.S. to the Paris Agreement and bring the country to net zero emissions by 2050, though his climate agenda will face immense constraints if Republicans retain control of the Senate.

In the past four years, the Trump administration has dismantled more than 70 key environmental regulations, with nearly 30 in the works.

“Regan will take over the helm of the EPA at perhaps the most critical moment in the agency’s history, and he has to do a lot more than just clean up the toxic mess Trump left behind,” said Kieran Suckling, executive director of the Center for Biodiversity.

If the GOP retains control of the Senate and hinders climate legislation, Biden’s plans will depend on the EPA to implement regulations to reduce fossil fuel emissions from sites and automobiles.

The Biden government is already planning to put restrictions on oil and gas drilling on public properties, block pipelines across the country and withdraw many of Trump’s executive orders for energy.

Categories
Health

UK regulator warns these with historical past of serious allergic reactions

Assistant Nurse Katie McIntosh gives Vivien McKay, Clinical Nurse Manager at Western General Hospital, the first of two Pfizer / BioNTech COVID-19 stitches on the first day of the largest vaccination program in UK history in Edinburgh, Scotland, UK December 8 2020.

Andrew Milligan | Reuters

LONDON – People with a history of “significant” allergic reactions should not receive the coronavirus vaccine developed by Pfizer and BioNTech, the UK Medicines Agency said on Wednesday.

The UK drug and health products regulator has updated its guidance to UK health care providers on who should get the vaccine after two members of the UK National Health Service had allergic reactions to the shot. Both are recovering well, according to the NHS national medical director.

“People with a history of significant allergic reaction to a vaccine, drug, or food (such as a history of anaphylactoid reaction or someone recommended to wear an adrenaline auto-injector) should not receive the Pfizer BioNtech vaccine received, “the regulator said.

Stephen Powis, national medical director for the NHS, said such a precaution was “common with new vaccines”.

The UK was the first country to approve and administer the Pfizer BioNTech vaccine. A massive vaccination campaign began on Tuesday that began in hospitals, with health and nursing home workers and those over 80 being vaccinated first.

Dr. June Raine, head of MHRA, told a UK government selection committee on Wednesday that the regulator would maintain “real-time vigilance” of the vaccine after its use.

“Last night we looked at two case reports of allergic reactions,” she said.

“We know from extensive clinical studies that this was not a feature. However, if we need to step up our advice after having this experience in vulnerable populations, the priority groups, we will get that advice on the spot immediately.”